Last reviewed 2026-05-13 · How we verify

VI-0521

VI-0521, marketed by Vivus LLC, is a small molecule drug with a key composition patent expiring in 2028. The drug's mechanism of action involves interacting with a specific target in the body, providing a unique therapeutic approach. The primary risk to VI-0521 is the patent expiration in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects (PHASE4)
• A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity (PHASE4)
• A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents (PHASE4)
• Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects (PHASE4)
• A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults (PHASE3)
• A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects. (PHASE2)
• A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults (PHASE1,PHASE2)
• Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• VI-0521 CI brief — competitive landscape report
• VI-0521 updates RSS · CI watch RSS
• Vivus Llc portfolio CI